EGFR and non-small cell lung carcinoma: In our case, the treatment with sintilimab plus bevacizumab conferred six months of PFS in the EGFR‐mutant patient with advanced NSCLC who had undergone multiline therapies, which demonstrate its powerful antitumor efficacy.